Cited by 146Cholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record.

Pharmacological Drug Treatment of Alzheimer Disease: The Cholinergic Hypothesis Revisited

Ladner, Christopher J., Lee, John M.·1998·Journal of Neuropathology & Experimental Neurology

DOI 10.1097/00005072-199808000-00001

Open this paper in CoChat — free account

Abstract

Christopher J. Ladner, PhD, John M. Lee, MD, PhD; Pharmacological Drug Treatment of Alzheimer Disease: The Cholinergic Hypothesis Revisited, Journal of Neu

Integrity signals

Registry

Crossref · 10.1097/00005072-199808000-00001

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

A review on cholinesterase inhibitors for Alzheimer’s disease
Anand, P., & Singh, B. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0036-3 · Cited by 722
Galantamine
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383
“[18-25] The cognitive deficits seen in patients with AD are thought to be primarily related to the degeneration of cholinergic neurons in the cortex and hippocampus (the cholinergic hypothesis of AD), resulting in deficits of cholinergic transmission and reduced levels of acetylcholine in these patients.[6,26-29] Howe…”
Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease
Kar, S., Slowikowski, S. P. M., Westaway, D. A., & Mount, H. T. J. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0442 · Cited by 366
“Cholinergic neurons in the brain stem and striatum are either spared or affected only in late stages of the disease.(45,47,48) Together with pharmacologic evidence of cholinergic involvement in the affected cognitive processes, these findings led to the development of a “cholinergic hypothesis” of AD.”
Influential
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review
Bryant, J., Clegg, A. P., Nicholson, T., McIntyre, L., Broe, S. D., Gerard, K., & Waugh, N. R. (2001) · Health Technology Assessment · doi:10.3310/hta5010 · Cited by 246
Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System
Felder, C. C., Bymaster, F. P., Ward, J. S., & DeLapp, N. W. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990607u · Cited by 235
Smoking, nicotine and neuropsychiatric disorders
Döme, P., Lazáry, J., Kalapos, M. P., & Rihmer, Z. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.013 · Cited by 227
Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
“It was also found that a reduction of the acetylcholine synthesizing enzyme (choline acetyltransferase, ChAT) correlates with the grade of dementia [55].”
Background
Disruption of the retinoid signalling pathway causes a deposition of amyloid β in the adult rat brain
Corcoran, J. P. T., So, P. L., & Maden, M. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03563.x · Cited by 195
“…markers choline acetyltransferase (chAT), which synthesizes acetylcholine, and acetylcholinesterase, which breaks down acetylcholine and, subsequently the loss of cholinergic neurons themselves (Coyle et al., 1983; Perry et al., 1992; Geula et al., 1998; Ladner & Lee, 1998; Talesa, 2001).”
Background
Familial Alzheimer's disease: Site of mutation influences clinical phenotype
Lippa, C. F., Swearer, J. M., Kane, K., Nochlin, D., Bird, T. D., Ghetti, B. F., Nee, L. E., George‐Hyslop, P. S., Pollen, D. A., & Drachman, D. A. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3 · Cited by 67
The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system
Hawkes, C. A., & Kar, S. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2003.11.002 · Cited by 159
Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis
Boncristiano, S., Calhoun, M. E., Kelly, P. H., Pfeifer, M., Bondolfi, L., Stalder, M., Phinney, A. L., Abramowski, D., Sturchler-Pierrat, C., Enz, A., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03234.2002 · Cited by 160
“…signal transduction, and significant reductions in choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) enzyme activities have been reported (Coyle et al., 1983; Perry et al., 1992; Ransmayr et al., 1992; Bierer et al., 1995; Jope et al., 1997; Geula et al., 1998; Ladner and Lee, 1998).”
Background
Cholinergic Treatments with Emphasis on M1 Muscarinic Agonists as Potential Disease-Modifying Agents for Alzheimer's Disease
Fisher, A. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.002 · Cited by 151
M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Jiang, S., Li, Y., Zhang, C., Zhao, Y., Bu, G., Xu, H., & Zhang, Y. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1406-z · Cited by 147
Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation
Thomas, T., Nadackal, T. G., & Thomas, K. (2001) · Neuroreport · doi:10.1097/00001756-200110290-00024 · Cited by 128
A review of rivastigmine: A reversible cholinesterase inhibitor
Williams, B. R., Nazarians, A., & Gill, M. A. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80160-1 · Cited by 122
Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation
Sharifi-Rad, J., Rapposelli, S., Sestito, S., Herrera-Bravo, J., Arancibia-Diaz, A., Salazar, L. A., Yeskaliyeva, B., Beyatli, A., Leyva-Gómez, G., González-Contreras, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091515 · Cited by 125
“The cholinergic hypothesis argues that the reduction of learning and mnemonic processes at the base of the disease are due to low levels of ACh in neurons; reduced ACh, is associated with an insufficient synthetic action of choline O-acetyltransferase (ChAt) and a high catalytic action of acetylcholinesterase (AChE),…”
Background
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning
Kabir, M. T., Uddin, M. S., Begum, M. M., Thangapandiyan, S., Rahman, M. S., Aleya, L., Mathew, B., Ahmed, M., Barreto, G. E., & Ashraf, G. M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191008103141 · Cited by 119
Protein kinase C isoforms as therapeutic targets in nervous system disease states
Battaini, F. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0893 · Cited by 115
Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity
Atanasova, M., Stavrakov, G., Philipova, I., Zheleva, D., Yordanov, N., & Doytchinova, I. A. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.07.058 · Cited by 95
The impact of Aβ-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice
Hu, L., Wong, T. P., Côté, S. L., Bell, K. F. S., & Cuello, A. C. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00394-4 · Cited by 90
M1 muscarinic receptor signaling in mouse hippocampus and cortex
Porter, A. C., Bymaster, F. P., DeLapp, N. W., Yamada, M., Wess, J., Hamilton, S. E., Nathanson, N. M., & Felder, C. C. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02721-x · Cited by 90
Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients.
Battaini, F., Pascale, A., Lucchi, L., Pasinetti, G., & Govoni, S. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7151 · Cited by 82
Neurophysiological support of consciousness during waking and sleep
Gottesmann, C. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00014-3 · Cited by 85
Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease
Hiremathad, A., Keri, R. S., Esteves, A. R., Cardoso, S. M., Chaves, S., & Santos, M. A. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.023 · Cited by 82
Cholinergic Stimulation Enhances Neural Activity Associated with Encoding but Reduces Neural Activity Associated with Retrieval in Humans
Kukolja, J., Thiel, C. M., & Fink, G. R. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0203-09.2009 · Cited by 86
“Whereas an abundance of research studies has concentrated on elucidating neuropharmacological alterations in AD (Ladner and Lee, 1998; Selkoe, 2002; Cummings et al., 2007; Bentley et al., 2008), there is comparatively little information about the development of neurotransmitter systems in healthy human aging.”
Background
Pharmacological effects of natural Ganoderma and its extracts on neurological diseases: A comprehensive review
Zhao, C., Zhang, C., Zheng, X., Ahmad, Z., Li, J., & Chang, M. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.10.076 · Cited by 80
Therapeutic Strategies in Alzheimer’s Disease: Ml Muscarinic Agonists
Fisher, A. (2000) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.84.101 · Cited by 80
AF150(S) and AF267B
Fisher, A., Brandeis, R., Bar-Ner, R. H. N., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I., & Pittel, Z. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0025-3 · Cited by 80
Formaldehyde toxicity in age-related neurological dementia
Kou, Y., Zhao, H., Cui, D., Han, H., & Tong, Z. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101512 · Cited by 82
“reduction of acetylcholine (Ach) levels in the brains lead to AD onset (Ladner and Lee, 1998; Wevers et al., 2000).”
Sympathetic Sprouting Drives Hippocampal Cholinergic Reinnervation That Prevents Loss of a Muscarinic Receptor-Dependent Long-Term Depression at CA3–CA1 Synapses
Scheiderer, C. L., McCutchen, E., Thacker, E. E., Kolasa, K., Ward, M. K., Parsons, D. S., Harrell, L. E., Dobrunz, L. E., & McMahon, L. L. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.5507-05.2006 · Cited by 78
“…PI turnover is compromised in humans with AD and in animal models after loss of cholinergic innervation (Pearce and Potter, 1991; Ferrari-DiLeo and Flynn, 1993; Ferrari-DiLeo et al., 1995; Ladner et al., 1995; Ladner and Lee, 1998; Potter et al., 1999, 2002; Muma et al., 2003; Kelly et al., 2005).”
Background
Recent Progress in Repositioning Alzheimer'S Disease Drugs Based on a Multitarget Strategy
Santos, M. A., Chand, K., & Chaves, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0103 · Cited by 79
Modulation of β-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors
Hellström‐Lindahl, E. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00028-5 · Cited by 76
Dysfunction of the Blood-Brain Barrier—A Key Step in Neurodegeneration and Dementia
Noe, C. R., Noe-Letschnig, M., Handschuh, P. A., Noe, C. A., & Lanzenberger, R. R. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00185 · Cited by 76
“Therefore, the therapy of AD includes the administration of acetylcholinesterase inhibitors (Ladner and Lee, 1998), substances that are meant to prevent the breakdown of acetylcholine.”
Background
Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer’s disease
Wu, W., Dai, Y.-C., Li, N., Dong, Z., Gu, T., Shi, Z., Xue, X., Tang, Y., & Duan, J. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1210139 · Cited by 75
Age-related alterations of GABAergic input to CA1 Pyramidal neurons and its control by nicotinic acetylcholine receptors in rat hippocampus
Potier, B., Jouvenceau, A., Epelbaum, J., & Dutar, P. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.06.040 · Cited by 72
The Cholinergic Deficiency Syndrome and Its Therapeutic Implications
Lemstra, A. W., Eikelenboom, P., & van Gool, W. A. (2002) · Gerontology · doi:10.1159/000066508 · Cited by 66
Insulin-Like Growth Factor-II/Cation-Independent Mannose 6-Phosphate Receptor in Neurodegenerative Diseases
Wang, Y., MacDonald, R. G., Thinakaran, G., & Kar, S. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9849-7 · Cited by 68
Neuroprotective Effects of Acetylcholinesterase Inhibitory Peptides from Anchovy (Coilia mystus) against Glutamate-Induced Toxicity in PC12 Cells
Zhao, T., Su, G., Wang, S., Zhang, Q., Zhang, J., Zheng, L. P., Sun, B., & Zhao, M. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b03945 · Cited by 65
High content screen microscopy analysis of Aβ1–42-induced neurite outgrowth reduction in rat primary cortical neurons: Neuroprotective effects of α7 neuronal nicotinic acetylcholine receptor ligands
Hu, M., Schurdak, M. E., Puttfarcken, P. S., Kouhen, R. E., Gopalakrishnan, M., & Li, J. (2007) · Brain Research · doi:10.1016/j.brainres.2007.03.051 · Cited by 60
G Protein–Coupled Receptors, Cholinergic Dysfunction, and Aβ Toxicity in Alzheimer’s Disease
Thathiah, A., & Strooper, B. D. (2009) · Science Signaling · doi:10.1126/scisignal.293re8 · Cited by 59
M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
Scarpa, M., Hesse, S., & Bradley, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2019.12.003 · Cited by 55
Differences in Kinetics of Xanomeline Binding and Selectivity of Activation of G Proteins at M1 and M2 Muscarinic Acetylcholine Receptors
Jakubík, J., El‐Fakahany, E. E., & Doležal, V. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023762 · Cited by 54
“This decrease in cholinergic input is not accompanied by changes in the density of postsynaptic M1 receptors (Ladner and Lee, 1998).”
Background
Novel 3-phenylcoumarin–lipoic acid conjugates as multi-functional agents for potential treatment of Alzheimer's disease
Jalili‐Baleh, L., Nadri, H., Forootanfar, H., Samzadeh‐Kermani, A., Küçükkılınç, T. T., Ayazgök, B., Rahimifard, M., Baeeri, M., Doostmohammadi, M., Firoozpour, L., et al. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.04.030 · Cited by 53
G Protein-Coupled Receptor Signaling Complexity in Neuronal Tissue:Implications for Novel Therapeutics
Maudsley, S. R., Martin, B., & Luttrell, L. M. (2007) · Current Alzheimer Research · doi:10.2174/156720507779939850 · Cited by 50
New Acetylcholinesterase‐Inhibitory Pregnane Glycosides of Cynanchum atratum Roots
Lee, K. Y., Sung, S. H., & Kim, Y. C. (2003) · Helvetica Chimica Acta · doi:10.1002/hlca.200390047 · Cited by 49
Anti-amyloidogenic and anti-apoptotic effect of α-bisabolol against Aβ induced neurotoxicity in PC12 cells
Shanmuganathan, B., Suryanarayanan, V., Sathya, S., Narenkumar, M., Singh, S. K., Kandasamy, R., & Devi, K. P. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.017 · Cited by 50
Interaction of anandamide with the M1 and M4 muscarinic acetylcholine receptors
Christopoulos, A., & Wilson, K. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02825-6 · Cited by 48
Functional Recovery of Cholinergic Basal Forebrain Neurons under Disease Conditions: Old Problems, New Solutions?
Härtig, W., Bauer, A., Brauer, K., Grosche, J., Hortobágyi, T., Penke, B., Schliebs, R., & Harkany, T. (2002) · Reviews in the Neurosciences · doi:10.1515/revneuro.2002.13.2.95 · Cited by 49
Deciphering the anti-apoptotic potential of α-bisabolol loaded solid lipid nanoparticles against Aβ induced neurotoxicity in Neuro-2a cells
Sathya, S., Shanmuganathan, B., & Devi, K. P. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.110948 · Cited by 47
Synthesis and Pharmacological Evaluation of Dimeric Muscarinic Acetylcholine Receptor Agonists
Christopoulos, A., Grant, M. K. O., Ayoubzadeh, N., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29501-x · Cited by 47
Neuroprotective effects of matrine on scopolamine-induced amnesia via inhibition of AChE/BuChE and oxidative stress
Sun, K., Bai, Y., Zhao, R., Guo, Z., Su, X., Li, P., & Yang, P. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0335-y · Cited by 46
Differences in regional and subcellular localization of Gq/11 and RGS4 protein levels in Alzheimer's disease: Correlation with muscarinic M1 receptor binding parameters
Muma, N. A., Mariyappa, R., Williams, K., & Lee, J. M. (2002) · Synapse · doi:10.1002/syn.10153 · Cited by 42
Self-citation
Constitutive overactivation of protein kinase C in guinea pig brain increases α‐secretory APP processing without decreasing β‐amyloid generation
Roßner, S., Beck, M., Stahl, T., Mendla, K. D., Schliebs, R., & Bigl, V. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00211.x · Cited by 41
Selective Extraction of Piceatannol from Passiflora edulis by-Products: Application of HSPs Strategy and Inhibition of Neurodegenerative Enzymes
dos Santos, L. C., Mendiola, J. A., Sánchez‐Camargo, A. D. P., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126248 · Cited by 39
“On the one hand, AChE is an important enzyme in the cholinergic system, responsible for the hydrolysis of acetylcholine, a neurotransmitter distributed all over the central nervous system [18].”
Background
GRK5 Deficiency Accelerates β-Amyloid Accumulation in Tg2576 Mice via Impaired Cholinergic Activity
Cheng, S., Li, L., He, S., Liu, J., Sun, Y., He, M., Grasing, K., Premont, R. T., & Suo, W. Z. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.170894 · Cited by 41
Biological evaluation of synthetic α,β-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation
Zha, G., Zhang, C., Qin, H., Jantan, I., Sher, M., Amjad, M. W., Hussain, M. A., Hussain, Z., & Bukhari, S. N. A. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.015 · Cited by 39
Persistent Binding and Functional Antagonism by Xanomeline at the Muscarinic M5 Receptor
Grant, M. K. O., & El‐Fakahany, E. E. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090134 · Cited by 38
“Although the disease is accompanied by a marked loss of presynaptic cholinergic neurons, postsynaptic M1 muscarinic receptors, which are involved in learning and memory, remain largely intact (Ladner and Lee, 1998).”
Background
Pharmacological models in Alzheimer's disease research
Gilles, C., & Ertle, S. (2000) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2000.2.3/cgilles · Cited by 38
Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population
Bono, G. F., Simão-Silva, D. P., Batistela, M. S., Josviak, N. D., Dias, P. F. R., do Nascimento, G. A., de Souza, R. L. R., Piovezan, M. R., de Souza, R. K. M., & Alle, L. F. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2014.12.009 · Cited by 37
Amyloid β peptides and central cholinergic neurons: functional interrelationship and relevance to Alzheimer's disease pathology
Kar, S., & Quirion, R. (2004) · Progress in brain research · doi:10.1016/s0079-6123(03)45018-8 · Cited by 37
Restorative Neurosurgery: Opportunities for Restoration of Function in Acquired, Degenerative, and Idiopathic Neurological Diseases
Thompson, T. P., Lunsford, L. D., & Kondziolka, D. S. (1999) · Neurosurgery · doi:10.1097/00006123-199910000-00001 · Cited by 36
Alkyl 2-(2-(arylidene)alkylhydrazinyl)thiazole-4-carboxylates: Synthesis, acetyl cholinesterase inhibition and docking studies
Haroon, M., Khalid, M., Shahzadi, K., et al. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131063 · Cited by 36
Dysfunction of G Protein-Coupled Receptor Kinases in Alzheimer's Disease
Suo, W. Z., & Li, L. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.154 · Cited by 37
“Although the detailed descriptions may evolve over time with increasing insights into the disease pathogenesis, the principal concepts of these hypotheses appear to stand solidly up to now[6,71,73,74,75,76,77,78].”
Background
Dynamic structure based pharmacophore modeling of the Acetylcholinesterase reveals several potential inhibitors
Shiri, F., Pirhadi, S., & Ghasemi, J. B. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1468281 · Cited by 35
“The most obvious clinical finding in AD represents that levels of acetylcholine (ACh), as a neurotransmitter responsible for the conduction of electrical impulses from one nerve cell to another, are decreased (Ladner & Lee, 1998; Mehta, Adem, & Sabbagh, 2011).”
Background
Muscarinic receptor-mediated GTP–Eu binding in the hippocampus and prefrontal cortex is correlated with spatial memory impairment in aged rats
Zhang, H.-Y., Watson, M. L., Gallagher, M., & Nicolle, M. M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.016 · Cited by 34
Tacrine–deferiprone hybrids as multi-target-directed metal chelators against Alzheimer's disease: a two-in-one drug
Chand, K., Rajeshwari, K., Candeias, E., Cardoso, S. M., Chaves, S., & Santos, M. A. (2018) · Metallomics · doi:10.1039/c8mt00143j · Cited by 33
Activation of melatonin receptor 1 by CRISPR‐Cas9 activator ameliorates cognitive deficits in an Alzheimer's disease mouse model
Park, H., & Kim, J. (2022) · Journal of Pineal Research · doi:10.1111/jpi.12787 · Cited by 33
“Instead, AD patients are currently treated with compounds that merely decelerate AD progression.(62,63) Several studies have reported that melatonin secretion is greatly inhibited in aged and AD patients.”
Background
Cholinesterase Inhibitory Potential of Quercetin towards Alzheimer’s Disease - A Promising Natural Molecule or Fashion of the Day? - A Narrowed Review
Orhan, İ. E. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666201119153807 · Cited by 34
Reduced High-Affinity Agonist Binding at the M1 Muscarinic Receptor in Alzheimer's Disease Brain: Differential Sensitivity to Agonists and Divalent Cations
Ladner, C. J., & Lee, J. M. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7116 · Cited by 31
Self-citation
Dihuang-Yinzi Alleviates Cognition Deficits via Targeting Energy-Related Metabolism in an Alzheimer Mouse Model as Demonstrated by Integration of Metabolomics and Network Pharmacology
Han, G., Zhen, W., Dai, Y., Yu, H., Li, D., & Ma, T. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.873929 · Cited by 30
Synthetic studies of himbacine, a potent antagonist of the muscarinic M2 subtype receptor 1. Stereoselective total synthesis and antagonistic activity of enantiomeric pairs of himbacine and (2′S,6′R)-diepihimbacine, 4-epihimbacine, and novel himbacine congeners
Takadoi, M., Katoh, T., Ishiwata, A., et al. (2002) · Tetrahedron · doi:10.1016/s0040-4020(02)01358-3 · Cited by 30
Flavanone glycosides as acetylcholinesterase inhibitors: computational and experimental evidence.
Remya, C., Dileep, K. V., Tintu, I., Variyar, E. J., & Sadasivan, C. (2014) · PubMed Central · Cited by 27
Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands
Davis, C. N., Bradley, S. R., Schiffer, H. H., et al. (2009) · BMC Pharmacology · doi:10.1186/1471-2210-9-14 · Cited by 28
“Xanomeline, N-desmethylclozapine (NDMC), AC260584 (4-[3-(4-butylpiperidin-1-yl)propyl]-7-fluoro2H-benzo[b][1,4]oxazin-3-one)), AC-42 (4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one), AC260515 (4-[3-(4-butyl-piperidin-1-yl)-propyl]-7-chloro2H-benzo[b][1,4]oxazin-3-one), AC-262469 (4-[3-(4cyclopropylmethyloxypip…”
Background
Synthesis of novel sulfamides incorporating phenethylamines and determination of their inhibition profiles against some metabolic enzymes
Aksu, K., Akıncıoğlu, H., Akıncıoğlu, A., et al. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201800150 · Cited by 26
Docking-based Design of Galantamine Derivatives with Dual-site Binding to Acetylcholinesterase
Stavrakov, G., Philipova, I., Zheleva‐Dimitrova, D., Atanasova, M., Konstantinov, S., & Doytchinova, I. A. (2016) · Molecular Informatics · doi:10.1002/minf.201600041 · Cited by 28
Evaluation of the nutritional profile and antioxidant and anti-cholinesterase activities ofPadina gymnospora(Phaeophyceae)
Shanmuganathan, B., & Devi, K. P. (2016) · European Journal of Phycology · doi:10.1080/09670262.2016.1218938 · Cited by 25
“Notable cholinergic changes are observed in patients with AD (Terry & Buccafusco, 2003) such as decreased ACh levels in the synaptic cleft due to its rapid hydrolysis by the enzyme acetylcholinesterase (AChE) (Lasner & Lee, 1998).”
Background
Effects of anandamide on the binding and signaling properties of M1 muscarinic acetylcholine receptors
Lanzafame, A. A., Guida, E., & Christopoulos, A. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.08.005 · Cited by 24
Synthesis and evaluation of novel carbamate-substituted flavanone derivatives as potent acetylcholinesterase inhibitors and anti-amnestic agents
Anand, P., & Singh, B. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0162-3 · Cited by 23
“The most potent test compound (5f0) was evaluated in vivo for memory restorative actions in scopolamine (0.4 mg/kg)- induced amnesia in mice by Morris water maze test.”
BackgroundInfluential
Pharmacological Analysis of the Novel Mode of Interaction between Xanomeline and the M1 Muscarinic Acetylcholine Receptor
Christopoulos, A., Parsons, A. M., & El‐Fakahany, E. E. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38262-x · Cited by 23
Alzheimer's disease: Its diagnosis and pathogenesis
Kril, J. J., & Halliday, G. M. (2001) · International review of neurobiology · doi:10.1016/s0074-7742(01)48016-0 · Cited by 22
Okadaic Acid and Hypoxia Induced Dementia Model of Alzheimer’s Type in Rats
Kaushal, A., Wani, W. Y., Bal, A., Gill, K. D., & Kaur, J. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-0005-9 · Cited by 21
Acetylcholinergic neurotransmission and the β-amyloid cascade: implications for Alzheimer’s disease
Verhoeff, N. P. L. G. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.2.277 · Cited by 21
Synthesis of a hybrid analog of the acetylcholinesterase inhibitors huperzine A and huperzine B
Rajendran, V., Rong, S.-B., Saxena, A., et al. (2001) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)01008-5 · Cited by 21
Impact of muscarinic agonists for successful therapy of Alzheimer’s disease
Fisher, A., Brandeis, R., Haring, R., Bar-Ner, N., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I., & Pittel, Z. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_18 · Cited by 19
QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine
Malone, K., & Hancox, J. C. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620942416 · Cited by 18
The Alzheimer s plaques tangles and memory deficits may have a common origin part V why is Ca sup 2 sup signal lower in the disease
Chen, M. (1999) · Frontiers in bioscience · doi:10.2741/a400 · Cited by 18
“It is also supported by a rapidly growing body of evidence emerging from various research areas ( 13-15 ).”
Background
Antiamnesic Effects of Walnuts Consumption on Scopolamine-Induced Memory Impairments in Rats.
Harandi, S., Golchin, L., Ansari, M., et al. (2015) · PubMed · Cited by 17
Diphenylsulfone muscarinic antagonists: piperidine derivatives with high m2 selectivity and improved potency
Billard, W., Binch, H., Bratzler, K., et al. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00437-6 · Cited by 17
Talsaclidine (WAL 2014 FU), a muscarinic M1 receptor agonist for the treatment of Alzheimer's disease
Wienrich, M., Ceci, A., Ensinger, H. A., Gaida, W., Mendla, K. D., Osugi, T., Raschig, A., & Weiser, T. W. (2002) · Drug Development Research · doi:10.1002/ddr.10085 · Cited by 17
Functional Compensation and Mechanism of Choline Acetyltransferase in the Treatment of Cognitive Deficits in Aged Dementia Mice
Zhu, Z., Zhang, L., Cui, Y., et al. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.05.016 · Cited by 16
Effects of muscarinic and adrenergic agonism on auditory P300 in the macaque
O’Neill, J., Halgren, E., Marinković, K., Siembieda, D. W., Refai, D., Fitten, L. J., Perryman, K. M., & Fisher, A. (2000) · Physiology & Behavior · doi:10.1016/s0031-9384(00)00258-4 · Cited by 16
“For example, P3 amplitude decline and latency retardation exceeding those observed in normal aging are long established in Alzheimer’s disease [42], but it is not known how these electrophysiological symptoms relate to the histochemically determined central cholinergic [23,25] and adrenergic [5,9,36,44] deficiencies o…”
Background
Erythrocyte membrane fluidity in mild cognitive impairment and Alzheimer's disease patients
Vignini, A., Alia, S., Pugnaloni, S., Giulietti, A., Bacchetti, T., Mazzanti, L., Luzzi, S., & Fiorini, R. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110754 · Cited by 15
Alzheimer′s Disease and Metals: A Review of the Involvement of Cellular Membrane Receptors in Metallosignalling
Amadoruge, P. C., & Barnham, K. J. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/542043 · Cited by 14
“Reductions in ChAT activity are the greatest [71, 72] and correlate with disease severity [68, 73].”
Background
Role of amyloid β peptides in the regulation of central cholinergic function and its relevance to Alzheimer's disease pathology
Kar, S. (2002) · Drug Development Research · doi:10.1002/ddr.10080 · Cited by 14
“…enzyme choline acetyltransferase (ChAT) in the neocortex of AD brains, which correlates positively with the clinical severity of dementia [Davies and Maloney, 1976; Whitehouse et al., 1982; Quirion, 1993; Geula and Mesulam, 1994; Kasa et al., 1997; Ladner and Lee, 1998; Blusztajn and Berse, 2000].”
Influential
Inhibitory Effect of Hexahydrocurcumin on Memory Impairment and Amyloidogenesis in Dexamethasone-Treated Mice
Jearjaroen, P., Pakdeepak, K., Tocharus, C., Chaichompoo, W., Suksamrarn, A., & Tocharus, J. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00269-y · Cited by 13
Choline pivaloyl ester strengthened the benefit effects of Tacrine and Galantamine on electroencephalographic and cognitive performances in nucleus basalis magnocellularis-lesioned and aged rats
Rispoli, V., Marra, R., Costa, N., Scipione, L., Rotiroti, D., Vita, D. D., Liberatore, F., & Carelli, V. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.06.009 · Cited by 13
Activation of muscarinic receptors inhibits glutamate-induced GSK-3β overactivation in PC12 cells
Ma, K., Yang, L., Chen, H., et al. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.42 · Cited by 13
Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells
Barik, J., Dajas‐Bailador, F., & Wonnacott, S. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706278 · Cited by 13
“AD, which accounts for 70% of dementia cases in most industrialised countries, is characterised by cell atrophy and extensive neurone loss, with a marked reduction in cholinergic transmission in the cortex and hippocampus (Coyle et al., 1983; Ladner & Lee, 1998).”
Background
Histochemical study of acute and chronic intraperitoneal nicotine effects on several glycolytic and Krebs cycle dehydrogenase activities in the frontoparietal cortex and subcortical nuclei of the rat brain
Turégano, L., Martínez-Rodríguez, R., Álvarez, M., Gragera, R., Segura, A., de Miguel, E., & Tolédano, A. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1116 · Cited by 12
“…(Kasa et al., 1997; Ladner and Lee, 1998; Lawrence and Sahakian, 1998; Bartus, 2000); but, up to now, “cholinergic therapies” have not obtained the expected success (Ladner and Lee, 1998; Lawrence and Sahakian, 1998; Samuels and Davis, 1998; Lemiere et al., 1999; Richards and Hendrie, 1999).”
Background
Synthetic studies on himbacine, a potent antagonist of the muscarinic M2 subtype receptor. Part 2: Synthesis and muscarinic M2 subtype antagonistic activity of the novel himbacine congeners modified at the C-3 position of lactone moiety
Takadoi, M., Yamaguchi, K., & Terashima, S. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00665-x · Cited by 12

Authors: Ladner, C. J., & Lee, J. M.
Affiliations: Loyola University Medical Center (US)
Corresponding author: Lee, John M.
ORCID: Lee, John M.
Venue: Journal of Neuropathology & Experimental Neurology
Publisher: Oxford University Press (OUP)
Published: 1998-08
Volume: 57
Issue: 8
Pages: 719-731
ISSN: 0022-3069 (ISSN-L)
1554-6578
DOI: 10.1097/00005072-199808000-00001
OpenAlex: W2061570982
Cited by: 142
References: 0
Citations by year: 2025: 2 · 2023: 3 · 2022: 8 · 2021: 4 · 2020: 7 · 2019: 3 · 2018: 8 · 2017: 3 · 2016: 7 · 2015: 4 · 2014: 4 · 2013: 5 · 2012: 1
FWCI: 7.08
Type: journal article
Language: en
Open access: closed
Locations: Journal of Neuropathology & Experimental Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Alzheimer's disease, cholinergic hypothesis, cholinesterase inhibitors, acetylcholinesterase, pharmacotherapy, cholinergic system
MeSH terms: Acetylcholine, Alzheimer Disease, Central Nervous System, Humans, Receptors, Muscarinic, Receptors, Nicotinic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacological Drug Treatment of Alzheimer Disease: The Cholinergic Hypothesis Revisited

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks